JP2013536168A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536168A5
JP2013536168A5 JP2013519858A JP2013519858A JP2013536168A5 JP 2013536168 A5 JP2013536168 A5 JP 2013536168A5 JP 2013519858 A JP2013519858 A JP 2013519858A JP 2013519858 A JP2013519858 A JP 2013519858A JP 2013536168 A5 JP2013536168 A5 JP 2013536168A5
Authority
JP
Japan
Prior art keywords
ylmethyl
alkylene
alkyl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013519858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536168A (ja
JP6081354B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044254 external-priority patent/WO2012009678A1/en
Publication of JP2013536168A publication Critical patent/JP2013536168A/ja
Publication of JP2013536168A5 publication Critical patent/JP2013536168A5/ja
Application granted granted Critical
Publication of JP6081354B2 publication Critical patent/JP6081354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013519858A 2010-07-16 2011-07-15 治療活性組成物およびそれらの使用方法 Active JP6081354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36507210P 2010-07-16 2010-07-16
US61/365,072 2010-07-16
PCT/US2011/044254 WO2012009678A1 (en) 2010-07-16 2011-07-15 Therapeutically active compositions and their method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016166461A Division JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2013536168A JP2013536168A (ja) 2013-09-19
JP2013536168A5 true JP2013536168A5 (https=) 2014-08-21
JP6081354B2 JP6081354B2 (ja) 2017-02-15

Family

ID=44629416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519858A Active JP6081354B2 (ja) 2010-07-16 2011-07-15 治療活性組成物およびそれらの使用方法
JP2016166461A Withdrawn JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016166461A Withdrawn JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Country Status (10)

Country Link
US (2) US20130184222A1 (https=)
EP (1) EP2593425B1 (https=)
JP (2) JP6081354B2 (https=)
CN (1) CN103097340B (https=)
AU (1) AU2011278998B2 (https=)
BR (1) BR112013001122B1 (https=)
CA (1) CA2805669C (https=)
ES (1) ES2704862T3 (https=)
MX (1) MX342951B (https=)
WO (1) WO2012009678A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
MX2014006072A (es) * 2011-11-25 2014-08-08 Bayer Ip Gmbh Derivados de 2-yodo-imidazol.
US9877962B2 (en) 2011-12-30 2018-01-30 Marc Henry Pitty Piperazinyl derivatives for the treatment of cancer
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150087600A1 (en) * 2012-01-19 2015-03-26 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US20150038541A1 (en) * 2012-03-19 2015-02-05 Aposignal Bioscience Llc Composition and methods for cell modulation
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2014184272A2 (en) * 2013-05-14 2014-11-20 Medizinische Hochschule Hannover Means and methods for treating cancer
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR101861869B1 (ko) * 2013-09-10 2018-05-28 경희대학교 산학협력단 신규한 비스-아미드 유도체 및 이의 용도
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
BR112017006425B8 (pt) * 2014-10-01 2023-05-16 Daiichi Sankyo Co Ltd Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos
JP6672288B2 (ja) * 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール
AU2015369712B2 (en) 2014-12-22 2020-05-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
JP6824954B2 (ja) * 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
ES2842448T3 (es) 2016-03-22 2021-07-14 Lianyungang Runzhong Pharmaceutical Co Ltd Compuesto de sultama y método de aplicación del mismo
TW201736341A (zh) * 2016-03-22 2017-10-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 丙啶磺醯胺類化合物及其使用方法
US9975885B2 (en) * 2016-04-28 2018-05-22 Purdue Research Foundation Broad-spectrum non-covalent coronavirus protease inhibitors
KR102707847B1 (ko) * 2017-09-22 2024-09-23 치아타이 티안큉 파마수티컬 그룹 주식회사 결정형 설파마이드 화합물
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721957D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
AU2019201137B2 (en) * 2018-02-20 2023-11-16 Darktrace Holdings Limited A cyber security appliance for a cloud infrastructure
CN108484522A (zh) * 2018-04-25 2018-09-04 山东百诺医药股份有限公司 4-(1,2,4-噁二唑-3-基)苯胺的制备方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109535025B (zh) * 2018-12-18 2022-09-09 尚科生物医药（上海）有限公司 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法
CN110283096A (zh) * 2019-07-03 2019-09-27 三峡大学 一种Cu-MOF催化的ɑ-胺基酰胺类化合物及其制备方法
MX2022014303A (es) * 2020-05-15 2022-12-07 Purdue Research Foundation Compuestos para el tratamiento del sars.
WO2022221686A1 (en) * 2021-04-15 2022-10-20 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
UY40000A (es) 2021-11-02 2023-05-31 Insilico Medicine Ip Ltd Inhibidores del sars-cov-2 para tratar infecciones por coronavirus
CN113845440A (zh) * 2021-11-04 2021-12-28 沈阳药科大学 基于ugi反应合成的非天然肽类idh1抑制剂及其制法和应用
CN118184599A (zh) * 2024-02-29 2024-06-14 重庆药友制药有限责任公司 一种阿莫奈韦中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016097A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
CN101137414A (zh) * 2004-12-31 2008-03-05 欧兰拓制药股份有限公司 多环双酰胺mmp抑制剂
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US8685660B2 (en) * 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

Similar Documents

Publication Publication Date Title
JP2013536168A5 (https=)
EP2968287B1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
KR102189529B1 (ko) 키누레닌 경로의 억제제
JP6309519B2 (ja) Ｎ置換ベンズアミド及びその使用方法
JP2015506985A5 (https=)
JP2010532386A5 (https=)
JP2019156852A (ja) Ａｓｋ１阻害剤の固体形態
JP2008535871A5 (https=)
JP2019513714A (ja) 置換ベンズアミド及びその使用方法
TW200817350A (en) Biaryloxymethylarenecarboxylic acids
JP2018519323A5 (https=)
RU2007141892A (ru) 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях
JP2010533715A5 (https=)
JP2010532387A5 (https=)
JP2004307440A (ja) ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
US7053094B2 (en) Compositions and methods for treating heart failure
SK2962002A3 (en) Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
RU2015144385A (ru) Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы
JP2019206529A (ja) 新規抗癌剤
JP2011506501A5 (https=)
KR20120092655A (ko) Ｃｎｓ 장애 치료용 옥사졸린 유도체
RU2005119644A (ru) 4-оксо-1-(3-замещенный фенил-1,4-дигидро-1,8-нафтиридин -3-карбоксамиды в качестве ингибиторов фосфодиэстеразы-4
RU2010132911A (ru) Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт)
WO2001070723A1 (en) Benzothiophene derivatives and medicinal use thereof
JP2008533063A5 (https=)